NCT01637623View on ClinicalTrials.gov

Study of Cardiovascular Disease and Obstructive Sleep Apnea

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)Hypertension
Interventions
DRUG

Losartan

Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.

DRUG

Allopurinol

Allopurinol 300 mg daily for 6 weeks

DRUG

Placebo

Placebo capsule daily for 6 weeks

Trial Locations (4)

53705

University of Wisconsin Madison, Madison

54308

Aurora Bay Care, Green Bay

54449

Marshfield Clinic, Marshfield

54601

Gundersen Lutheran, La Crosse

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT01637623 - Study of Cardiovascular Disease and Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter